GILD - National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection | Benzinga
U.S. National Institutes of Health has launched two clinical trials to examine a novel long-acting form of HIV pre-exposure prophylaxis (PrEP) in cisgender women and people who inject drugs.
The mid-stage studies will assess the safety, acceptability, and pharmacokinetics (how a drug moves through the body) of lenacapavir, an antiretroviral drug administered by injection every six months.
Gilead Sciences Inc. (NASDAQ:GILD) sponsored and funded the studies implemented through the HIV Prevention Trails Network (HPTN).
The HPTN is supported by grants from the National Institutes ...